Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-2: Maridebart Cafraglutide in Adults With Type 2 Diabetes Mellitus and Obesity or Overweight
jRCT2031250038Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Mar 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
01
Overview
Phase 3, randomised, double-blind trial of maridebart cafraglutide in type 2 diabetes mellitus (T2DM), obesity and Overweight (4 arms), sponsored by Amgen. Primary endpoint: Percent Change from Baseline in Body Weight at Week 72. Started Mar 2025; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on jRCT2031250038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250038.